Preventive effects of ulinastatin on complications related to pancreaticoduodenectomy A Consort-prospective, randomized, double-blind, placebo-controlled trial

Medicine (United States)

Volumn 95, Issue 24, 2016, Pages

  Zhang, Hao ^a   Tan, Chunlu ^a   Wang, Xing ^a   Kang, Deying ^a   Chen, Yonghua ^a   Xiong, Junjie ^a   Tian, Bole ^a   Li, Kezhou ^a   Hu, Weiming ^a   Chen, Xiaoli ^a   Ke, Nengwen ^a   Li, Ang ^a   Liu, Xubao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Pancreaticoduodenectomy; Postoperative pancreatic fistula; Ulinastatin

Indexed keywords

ULINASTATIN; GLYCOPROTEIN; TRYPSIN INHIBITOR;

ABDOMINAL INFECTION; ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; ADULT; ARTICLE; BILE LEAKAGE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTESTINE OBSTRUCTION; LAPAROTOMY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PANCREAS FISTULA; PANCREATIC DUCT; PANCREATICODUODENECTOMY; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PANCREATIC FISTULA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; RISK FACTOR; SEPTICEMIA; SEROPERITONEUM; STOMACH EMPTYING; SURGICAL INFECTION; ADVERSE EFFECTS; DOSE RESPONSE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; PANCREATIC NEOPLASMS; POSTOPERATIVE COMPLICATIONS; TIME FACTOR; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRYPSIN INHIBITORS;

EID: 84976385004     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003731     Document Type: Article

References (37)

1. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-17.
2. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999;229:613-22.
3. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273-9.
4. Phan GQ, Yeo CJ, Cameron JL, et al. Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients. Surgery 1997;122:989-6.
5. Barens SA, Lillemoe KD, Kaufman HS, et al. Pancreaticoduodenectomy for benign disease. Am J Surg 1996;171:131-4.
6. Burcharth F, Olsen SD, Trillingsgaard J, et al. Pancreaticoduodenectomy for periampullary cancer in patients more than 70 years of age. Hepatogastroenterology 2001;48:1149-52.
7. Lieberman MD, Kilburn H, Lindsey M, et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222:638-45.
8. Buchler MW, Wagner M, Schmied BM, et al. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 2003;138:1310-4.
9. Bassi C, Falconi M, Salvia R, et al. Management of complications after pancreaticoduodenectomy in a high volume centre: results on 150 consecutive patients. Digest Surg 2001;18:453-7.
10. Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786-95.
11. Lermite E, Sommacale D, Piardi T, et al. Complications after pancreatic resection: diagnosis, prevention and management. Clin Res Hepatol Gastroenterol 2013;37:230-9.
12. Butturini G, Daskalaki D, Molinari E, et al. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg 2008;15:247-51.
13. Ho CK, Kleeff J, Friess H, et al. Complications of pancreatic surgery. HPB 2005;7:99-108.
14. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006;244:931-7.
15. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8-13.
16. Satoi S, Toyokawa H, Yanagimoto H, et al. Is a nonstented duct-to-mucosa anastomosis using the modified Kakita method a safe procedure? Pancreas 2010;39:165-70.
17. Sutton CD, Garcea G, White SA, et al. Isolated Roux-loop pancreati-cojejunostomy: a series of 61 patients with zero postoperative pancreaticoenteric leaks. J Gastrointest Surg 2004;8:701-5.
18. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419-29.
19. Ohnishi H, Kosuzume H, Ashida Y, et al. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sci 1984;29:26-32.
20. Oda T, Miyawaki T, Sameshima T, et al. Antishock effects of urinary trypsin inhibitor, MR-20. Masui. Jpn J Anesthesiol 1984;33:137-42.
21. Okuhama Y, Shiraishi M, Higa T, et al. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999;82:34-2.
22. Xiong JJ, Altaf K, Mukherjee R, et al. Systematic review and meta-analysis of outcomes after intraoperative pancreatic duct stent placement during pancreaticoduodenectomy. Br J Surg 2012;99:1050-61.
23. Kurumboor P, Palaniswami KN, Pramil K, et al. Octreotide does not prevent pancreatic fistula following pancreatoduodenectomy in patients with soft pancreas and non-dilated duct: a prospective randomized controlled trial. J Gastrointest Surg 2015;19:2038-44.
24. Pederzoli P, Bassi C, Falconi M, et al. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin. Surg Gynecol Obstet 1986;163:428-32.
25. Prinz RA, Pickleman J, Hoffman JP. Treatment of pancreatic cutaneous fistulas with a somatostatin analog. Am J Surg 1988;155:36-42.
26. Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997;226:632-41.
27. Droeser RA, Jeanmonod P, Schuld J, et al. Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery. Dig Surg 2012;29:484-91.
28. Noda H, Kamiyama H, Kato T, et al. Risk factor for pancreatic fistula after pancreaticoduodenectomy performed by a surgeon during a learning curve: analysis of a single surgeon's experiences of 100 consecutive patients. Hepatogastroenterology 2012;59:1990-3.
29. Ramacciato G, Mercantini P, Petrucciani N, et al. Risk factors of pancreatic fistula after pancreaticoduodenectomy: a collective review. Am Surg 2011;77:257-69.
30. Lermite E, Pessaux P, Brehant O, et al. Risk factors of pancreatic fistula and delayed gastric emptying after pancreaticoduodenectomy with pancreaticogastrostomy. J Am Coll Surg 2007;204:588-96.
31. Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP 2007;8(4 suppl):488-94.
32. Berberat PO, Friess H, Kleeff J, et al. Prevention and treatment of complications in pancreatic cancer surgery. Dig Surg 1999;16:327-6.
33. Yang YM, Tian XD, Zhuang Y, et al. Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol 2005;11: 2456-1.
34. Tajima Y, Kuroki T, Tsutsumi R, et al. Risk factors for pancreatic anastomotic leakage: the significance of preoperative dynamic magnetic resonance imaging of the pancreas as a predictor of leakage. J Am Coll Surg 2006;202:723-1.
35. Pratt WB, Callery MP, Vollmer CM Jr. Risk prediction for development of pancreatic fistula using the ISGPF classification scheme. World J Surg 2008;32:419-28.
36. Akamatsu N, Sugawara Y, Komagome M, et al. Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage. J Hepatobiliary Pancreat Sci 2010;17:322-8.
37. Lin JW, Cameron JL, Yeo CJ, et al. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastro-intest Surg 2004;8:951.